First-in-man trial of CAP 7.1 in patients with heavily treated solid tumours.

Trial Profile

First-in-man trial of CAP 7.1 in patients with heavily treated solid tumours.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs CAP 7.1 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors CellAct Pharma
  • Most Recent Events

    • 07 Jun 2016 Results assessing pooled population pharmacokinetics from this and other Phase II trial (n=39) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 03 Jun 2016 According to a CellAct Pharma media release, pooled population pharmacokinetic data from this and a phase II study (see profile 222582) were presented at the 52nd Annual Meeting of the American Society for Clinical Oncology (ASCO).
    • 03 Jun 2016 Results of pooled population pharmacokinetic data from this and a phase II study (see profile 222582) published in a CellAct Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top